• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过口服灌胃评估表没食子儿茶素没食子酸酯 (EGCG) 在年轻成年唐氏综合征小鼠中的治疗潜力。

Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice.

机构信息

IUPUI Department of Psychology, 402 North Blackford Street, LD 124, Indianapolis, IN, 46202-3275, USA.

IUPUI Department of Biology, 723 West Michigan Street; SL 306, Indianapolis, IN, 46202-3275, USA.

出版信息

Sci Rep. 2020 Jun 26;10(1):10426. doi: 10.1038/s41598-020-67133-z.

DOI:10.1038/s41598-020-67133-z
PMID:32591597
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7319987/
Abstract

Epigallocatechin-3-gallate (EGCG) is a candidate therapeutic for Down syndrome (DS) phenotypes based on in vitro inhibition of DYRK1A, a triplicated gene product of Trisomy 21 (Ts21). Consumption of green tea extracts containing EGCG improved some cognitive and behavioral outcomes in DS mouse models and in humans with Ts21. In contrast, treatment with pure EGCG in DS mouse models did not improve neurobehavioral phenotypes. This study tested the hypothesis that 200 mg/kg/day of pure EGCG, given via oral gavage, would improve neurobehavioral and skeletal phenotypes in the Ts65Dn DS mouse model. Serum EGCG levels post-gavage were significantly higher in trisomic mice than in euploid mice. Daily EGCG gavage treatments over three weeks resulted in growth deficits in both euploid and trisomic mice. Compared to vehicle treatment, EGCG did not significantly improve behavioral performance of Ts65Dn mice in the multivariate concentric square field, balance beam, or Morris water maze tasks, but reduced swimming speed. Furthermore, EGCG resulted in reduced cortical bone structure and strength in Ts65Dn mice. These outcomes failed to support the therapeutic potential of EGCG, and the deleterious effects on growth and skeletal phenotypes underscore the need for caution in high-dose EGCG supplements as an intervention in DS.

摘要

没食子酸表没食子儿茶素酯(EGCG)是唐氏综合征(DS)表型的候选治疗药物,其基于体外抑制 DYRK1A,该基因是 21 号三体(Ts21)的三倍产物。绿茶提取物中含有的 EGCG 可改善 DS 小鼠模型和 Ts21 人类患者的一些认知和行为结果。相比之下,在 DS 小鼠模型中,用纯 EGCG 治疗并未改善神经行为表型。本研究检验了以下假说,即通过口服灌胃给予 200mg/kg/天的纯 EGCG 可改善 Ts65Dn DS 小鼠模型的神经行为和骨骼表型。灌胃后,三体小鼠的血清 EGCG 水平明显高于二倍体小鼠。三周的每日 EGCG 灌胃处理导致二倍体和三体小鼠均出现生长缺陷。与载体处理相比,EGCG 并未显著改善 Ts65Dn 小鼠在多元同心方场、平衡木或 Morris 水迷宫任务中的行为表现,但降低了游泳速度。此外,EGCG 导致 Ts65Dn 小鼠皮质骨结构和强度降低。这些结果未能支持 EGCG 的治疗潜力,并且对生长和骨骼表型的有害影响强调了在 DS 中作为干预措施使用高剂量 EGCG 补充剂需要谨慎。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6091/7319987/c4058d3fbcd0/41598_2020_67133_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6091/7319987/0151f8988346/41598_2020_67133_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6091/7319987/3c07fe54ac4c/41598_2020_67133_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6091/7319987/3e2c15f71c04/41598_2020_67133_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6091/7319987/f1415b50482c/41598_2020_67133_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6091/7319987/04bacb3e4faf/41598_2020_67133_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6091/7319987/34e32ca88da6/41598_2020_67133_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6091/7319987/c4058d3fbcd0/41598_2020_67133_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6091/7319987/0151f8988346/41598_2020_67133_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6091/7319987/3c07fe54ac4c/41598_2020_67133_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6091/7319987/3e2c15f71c04/41598_2020_67133_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6091/7319987/f1415b50482c/41598_2020_67133_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6091/7319987/04bacb3e4faf/41598_2020_67133_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6091/7319987/34e32ca88da6/41598_2020_67133_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6091/7319987/c4058d3fbcd0/41598_2020_67133_Fig7_HTML.jpg

相似文献

1
Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice.通过口服灌胃评估表没食子儿茶素没食子酸酯 (EGCG) 在年轻成年唐氏综合征小鼠中的治疗潜力。
Sci Rep. 2020 Jun 26;10(1):10426. doi: 10.1038/s41598-020-67133-z.
2
Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.表没食子儿茶素没食子酸酯(EGCG)摄入未能改善唐氏综合征 Ts65Dn 模型的行为缺陷,反而对骨骼表型有害。
Physiol Behav. 2017 Aug 1;177:230-241. doi: 10.1016/j.physbeh.2017.05.003. Epub 2017 May 3.
3
Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model.含表没食子儿茶素-3-没食子酸酯的补充剂对纠正唐氏综合征小鼠模型骨骼缺陷的不同作用。
Mol Nutr Food Res. 2016 Apr;60(4):717-726. doi: 10.1002/mnfr.201500781. Epub 2016 Feb 11.
4
Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.表没食子儿茶素没食子酸酯(EGCG)的剂量增加和治疗时间延长会对正常小鼠和唐氏综合征小鼠模型的骨骼参数产生负面影响。
PLoS One. 2022 Feb 23;17(2):e0264254. doi: 10.1371/journal.pone.0264254. eCollection 2022.
5
Green tea extracts containing epigallocatechin-3-gallate modulate facial development in Down syndrome.绿茶提取物中含有的表没食子儿茶素没食子酸酯可调节唐氏综合征患者的面部发育。
Sci Rep. 2021 Feb 25;11(1):4715. doi: 10.1038/s41598-021-83757-1.
6
Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model.青春期开始的低剂量表没食子儿茶素没食子酸酯(EGCG)治疗并不能改善唐氏综合征小鼠模型中的认知障碍。
Pharmacol Biochem Behav. 2015 Nov;138:70-9. doi: 10.1016/j.pbb.2015.09.002. Epub 2015 Sep 10.
7
Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.表没食子儿茶素-3-没食子酸酯对唐氏综合征Ts65Dn小鼠模型海马发育的新生儿药物治疗的短期和长期影响。
Neuroscience. 2016 Oct 1;333:277-301. doi: 10.1016/j.neuroscience.2016.07.031. Epub 2016 Jul 25.
8
Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.雄性和雌性唐氏综合征模型小鼠的骨骼缺陷是独立于成骨细胞中正常表达的 Dyrk1a 引起的。
Genes (Basel). 2021 Oct 28;12(11):1729. doi: 10.3390/genes12111729.
9
Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.没食子儿茶素没食子酸酯,一种 DYRK1A 抑制剂,可挽救唐氏综合征小鼠模型和人类的认知缺陷。
Mol Nutr Food Res. 2014 Feb;58(2):278-88. doi: 10.1002/mnfr.201300325. Epub 2013 Sep 14.
10
Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.产前表没食子儿茶素没食子酸酯(EGCG)治疗及双重特异性酪氨酸磷酸化调节激酶1A(Dyrk1a)剂量降低对与唐氏综合征相关颅面特征的影响。
Hum Mol Genet. 2016 Nov 15;25(22):4856-4869. doi: 10.1093/hmg/ddw309.

引用本文的文献

1
An approach to characterize mechanisms of action of anti-amyloidogenic compounds in vitro and in situ.一种在体外和原位表征抗淀粉样蛋白生成化合物作用机制的方法。
NPJ Parkinsons Dis. 2025 May 10;11(1):122. doi: 10.1038/s41531-025-00966-5.
2
Sex-specific trisomic Dyrk1a-related skeletal phenotypes during development in a Down syndrome model.唐氏综合征模型发育过程中性别特异性的 Dyrk1a 相关骨骼表型。
Dis Model Mech. 2024 Sep 1;17(9). doi: 10.1242/dmm.050914. Epub 2024 Sep 23.
3
Sex specific emergence of trisomic -related skeletal phenotypes in the development of a Down syndrome mouse model.

本文引用的文献

1
Plasticity as a therapeutic target for improving cognition and behavior in Down syndrome.唐氏综合征认知和行为改善的治疗靶点:可塑性。
Prog Brain Res. 2020;251:269-302. doi: 10.1016/bs.pbr.2019.11.001. Epub 2019 Dec 6.
2
Adolescent Exploratory Strategies and Behavioral Types in the Multivariate Concentric Square Field Test.多元同心方场试验中的青少年探索策略与行为类型
Front Behav Neurosci. 2019 Mar 4;13:41. doi: 10.3389/fnbeh.2019.00041. eCollection 2019.
3
The safety of green tea and green tea extract consumption in adults - Results of a systematic review.
唐氏综合征小鼠模型发育过程中三体相关骨骼表型的性别特异性出现。
bioRxiv. 2024 May 26:2024.05.24.595804. doi: 10.1101/2024.05.24.595804.
4
Pleiotropic effects of trisomy and pharmacologic modulation on structural, functional, molecular, and genetic systems in a Down syndrome mouse model.三体和药物调节对唐氏综合征小鼠模型结构、功能、分子和遗传系统的多效性影响。
Elife. 2024 Mar 18;12:RP89763. doi: 10.7554/eLife.89763.
5
Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model.唐氏综合征小鼠模型大脑中 DYRK1A 表达的性别特异性发育变化。
Neurobiol Dis. 2024 Jan;190:106359. doi: 10.1016/j.nbd.2023.106359. Epub 2023 Nov 20.
6
Overexpression screen of chromosome 21 genes reveals modulators of Sonic hedgehog signaling relevant to Down syndrome.21 号染色体基因过表达筛选揭示与唐氏综合征相关的 Sonic hedgehog 信号通路调节剂。
Dis Model Mech. 2023 Apr 1;16(4). doi: 10.1242/dmm.049712. Epub 2023 Apr 13.
7
A Comprehensive Review on Anti-Inflammatory Response of Flavonoids in Experimentally-Induced Epileptic Seizures.黄酮类化合物在实验性癫痫发作中抗炎反应的综合综述
Brain Sci. 2023 Jan 5;13(1):102. doi: 10.3390/brainsci13010102.
8
Green Tea Catechins Modulate Skeletal Development with Effects Dependent on Dose, Time, and Structure in a down Syndrome Mouse Model.绿茶儿茶素通过剂量、时间和结构依赖的方式调节唐氏综合征小鼠模型的骨骼发育。
Nutrients. 2022 Oct 7;14(19):4167. doi: 10.3390/nu14194167.
9
Effect of Epigallocatechin-3-gallate on Stress-Induced Depression in a Mouse Model: Role of Interleukin-1β and Brain-Derived Neurotrophic Factor.没食子酸表没食子儿茶素酯对小鼠应激诱导性抑郁的影响:白细胞介素-1β和脑源性神经营养因子的作用。
Neurochem Res. 2022 Nov;47(11):3464-3475. doi: 10.1007/s11064-022-03707-9. Epub 2022 Aug 8.
10
Fatty Acids: A Safe Tool for Improving Neurodevelopmental Alterations in Down Syndrome?脂肪酸:改善唐氏综合征神经发育障碍的安全工具?
Nutrients. 2022 Jul 13;14(14):2880. doi: 10.3390/nu14142880.
绿茶和绿茶提取物在成年人中的安全性——系统评价的结果。
Regul Toxicol Pharmacol. 2018 Jun;95:412-433. doi: 10.1016/j.yrtph.2018.03.019. Epub 2018 Mar 24.
4
DMSO: A Mixed-Competitive Inhibitor of Human Acetylcholinesterase.二甲基亚砜:人类乙酰胆碱酯酶的混合型竞争性抑制剂。
ACS Chem Neurosci. 2017 Dec 20;8(12):2618-2625. doi: 10.1021/acschemneuro.7b00344. Epub 2017 Oct 16.
5
Repeated dose studies with pure Epigallocatechin-3-gallate demonstrated dose and route dependant hepatotoxicity with associated dyslipidemia.对表没食子儿茶素没食子酸酯进行的重复给药研究表明,其具有剂量和给药途径依赖性肝毒性,并伴有血脂异常。
Toxicol Rep. 2016 Mar 5;3:336-345. doi: 10.1016/j.toxrep.2016.03.001. eCollection 2016.
6
Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.靶向三体性疾病的治疗:优化双重特异性酪氨酸磷酸化调节激酶1A(Dyrk1a)抑制作用以改善唐氏综合征缺陷。
Mol Genet Genomic Med. 2017 Sep 20;5(5):451-465. doi: 10.1002/mgg3.334. eCollection 2017 Sep.
7
The use of dimethylsulfoxide as a solvent in enzyme inhibition studies: the case of aldose reductase.二甲基亚砜在酶抑制研究中作为溶剂的应用:以醛糖还原酶为例。
J Enzyme Inhib Med Chem. 2017 Dec;32(1):1152-1158. doi: 10.1080/14756366.2017.1363744.
8
Safety assessment of green tea based beverages and dried green tea extracts as nutritional supplements.基于绿茶的饮料和干绿茶提取物作为营养补充剂的安全性评估。
Toxicol Lett. 2017 Aug 5;277:104-108. doi: 10.1016/j.toxlet.2017.06.008. Epub 2017 Jun 24.
9
The efficacy of Epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer's disease: an overview of pre-clinical studies and translational perspectives in clinical practice.表没食子儿茶素-3-没食子酸酯(绿茶)治疗阿尔茨海默病的疗效:临床前研究综述及临床实践中的转化前景
Infect Agent Cancer. 2017 Jun 19;12:36. doi: 10.1186/s13027-017-0145-6. eCollection 2017.
10
Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice.Dyrk1A 过表达导致 Ts65Dn 唐氏综合征小鼠 3R-tau 表达增加和认知缺陷。
Sci Rep. 2017 Apr 4;7(1):619. doi: 10.1038/s41598-017-00682-y.